Skip to main content

August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

FDA Approvals
Anti–PD-1 Antibodies for NSCLC and Renal Carcinoma
Caroline Helwick
Read More
Prostate Cancer
Upfront Docetaxel Markedly Improves Survival in Metastatic Prostate Cancer, at Reduced Cost
Wayne Kuznar
Read More
FDA Approvals
Enthusiasm Sky High for Immunotherapy with Anti–PD-1 Agents in Cancer
Caroline Helwick
Read More
Generic Docetaxel Increases Risk of Neutropenia, Costs
Caroline Helwick
Read More
Financial Distress Experienced by 40% of Patients with Cancer
Caroline Helwick
Read More
Should Oncologists Consider Interests of Society at Large When Treating the Individual Patient?
Wayne Kuznar
Read More
Even When Adjusting for Improved Survival, Newer Cancer Drugs More Expensive Than Older Ones
Wayne Kuznar
Read More
ASCO Workgroup Proposes Consolidated Payments
Caroline Helwick
Read More
Patients with Cancer Are Not Asking for Costly, Excessive Treatments
Wayne Kuznar
Read More
FDA Approvals
2014 Oncology Pipeline Looks Impressive
Caroline Helwick, Wayne Kuznar
Read More
Page 3 of 4
Results 21 - 30 of 32